Log In
Print
BCIQ
Print
Print this Print this
 

NP-1998 (formerly NGX-1998)

  Manage Alerts
Collapse Summary General Information
Company NeurogesX Inc.
DescriptionTopical liquid formulation of synthetic capsaicinin
Molecular Target Transient receptor potential vanilloid 1 (TRPV1) (VR1)
Mechanism of ActionTransient receptor potential vanilloid 1 (TRPV1) (VR1) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat neuropathic pain; Treat peripheral neuropathic pain; Treat postherpetic neuralgia (PHN)
Regulatory Designation

Partner

Acorda Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$158.6M

$56.5M

$97.1M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today